Thoracic Malignancy Steering Committee

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

The NCI Thoracic Malignancy Steering Committee (TMSC) was established in 2008.

Mission Statement

The TMSC functions to harmonize an efficient, cost-effective, science-driven, and transparent process that will identify and promote the "Best Science" in clinical research of lung and other thoracic malignancies by addressing the design and prioritization of phase 3 trials and large phase 2 studies in chest malignancies. In addition to focusing on lung cancer, the TMSC addresses oncology trials in other thoracic sites, such as mesothelioma. Esophageal cancer trials are reviewed by the Gastrointestinal Steering Committee.

Roster of Thoracic Malignancy Steering Committee (TMSC) members

TMSC Activities

Clinical Trials Planning Meetings (CTPMs)

  • Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer – February 2012


Clinical Trials

The following are clinical trials that were approved at the concept stage by the Steering Committee:

Trial ID NCT ID Trial Title
RTOG-0937 NCT01055197 Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)
RTOG-1106 NCT01507428 Randomized Phase II Trial of Individualized Adaptive Radiation Using During-Treatment FDG-PET/CT and Modern Radiation Technology to Dose Escalate in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
ECOG-E2511 NCT01642251 Phase II Randomized Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
RTOG-1306/ALLIANCE_31101 NCT01822496 A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)
RTOG-1308 NCT01993810 Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
SWOG-S1400 NCT02154490 Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
SWOG-S1300 NCT02134912 A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-Squamous NSCLC Patients who have Progressed Systemically after Previous Clinical Benefit from Crizotinib Monotherapy



NCT02193282 Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
ECOG-E4512 NCT02201992 A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
RTOG-1021 NCT01336894 A Randomized Phase III Study of Sublobar Resection (+/- Brachytherapy) Versus Stereotactic Body Radiation Therapy in High Risk Patients With Stage I Non-Small Cell Lung Cancer (NSCLC)
SWOG-S1403 NCT02438722 A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC)
RTOG-1327 NCT02186847 Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer (NSCLC)

Find all NCI-sponsored clinical trials.

CCCT Contact: Wolf Lindwasser, Ph.D.